Morphotek

European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009

Exton, Pennsylvania (ots/PRNewswire) - - Upon Marketing Authorization Orphan Status Would Provide for Ten Years of Market Exclusivity in the European Union for Both Investigational Treatments Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the European Commission has granted orphan drug status to the monoclonal ...